Related Experiment Videos
What is preferable in unstable angina, beta-blockade or calcium-inhibition?
Insights
Calcium antagonists like nifedipine reduce cardiac mechanical tension and dilate arteries, proving effective for unstable angina. They are often more beneficial than beta-blockers in managing coronary artery spasm.
Area of Science:
- Pharmacology
- Cardiology
- Vascular Medicine
Background:
- Nifedipine acts as a potent calcium antagonist, inhibiting excitation-contraction coupling with minimal side effects at therapeutic doses.
- Calcium antagonists are effective vasodilators, particularly for peripheral and coronary arteries, by reducing calcium influx into smooth muscle cells.
- Beta-blockers (e.g., propranolol, metoprolol) reduce cardiac workload by decreasing heart rate and blood pressure via beta-adrenoceptor blockade.
Purpose of the Study:
- To compare the efficacy of calcium antagonists versus beta-blockers in managing unstable angina (UA).
- To investigate the role of coronary vascular tone and spasm in UA.
- To determine the optimal therapeutic strategy for patients with unstable angina.
Main Methods:
- Review of nifedipine's mechanism of action as a calcium antagonist.
- Analysis of beta-blocker effects on cardiac function and vascular tone.
- Clinical observation of unstable angina patients treated with beta-blockers and subsequently with added nifedipine.
Main Results:
- Nifedipine reduces cardiac mechanical tension and dilates arteries, decreasing afterload and increasing coronary perfusion.
- Beta-blockade may worsen chest pain in conditions like Prinzmetal's syndrome due to unopposed alpha-adrenergic tone.
- In 52 unstable angina patients unresponsive to beta-blockade, adding nifedipine led to symptom relief in 42 within 2 hours.
Conclusions:
- Calcium antagonists, particularly nifedipine, demonstrate a significant role in managing unstable angina, especially when coronary spasm is implicated.
- The need for spasmolytic therapy with calcium antagonists may outweigh the need for beta-blockade in certain unstable angina cases.
- While both drug classes may be used, the precise comparative value of calcium antagonists and beta-blockers in unstable angina requires further investigation.
Abstract:
Nifedipine is a strong calcium antagonist; it blocks the excitation-contraction coupling, yet at therapeutic dosage levels it has few side effects. It is said that a single molecule of nifedipine can neutralize the effects of several thousand calcium ions in the excitation-process. Thus this agent reduces the ability of the cardiac cells to develop mechanical tension yet it does not affect electrical excitation. Calcium antagonists are also potent dilators, particularly of the arteries on the periphery of the human body and in the coronary arterial system. The basic mode of action is thought to be the same, i.e. reduction of the calcium transport, this time into the smooth muscle cells of the arterial wall, thus "forcing' the arteriole to dilate. The resultant action is a reduction in afterload, while there is an increase in perfusion of the coronary vascular bed. Thus there is a dual action, the one centrally, the other peripherally both of which will be particularly effective in patients with unstable angina (UA) in whom excess coronary vascular tone is suspected. Beta-blockers, particularly propranolol and metoprolol, with which we have the most experience, work via beta 2 adrenoceptor blockade in the heart. Cardiac frequency decreases, arrhythmias are suppressed, blood pressure may decrease, all reducing cardiac work. If in UA variations in coronary vascular tone and frank spasm do occur then is would be more logical to use Ca-antagonists instead of beta-blockade. Our clinical experience to date has not shown that patients with UA are worsened by propranolol or metoprolol but there are scores of clinical reports showing worsening of chest pain in Prinzmetal's syndrome, presumably because beta-blockade leads to excessive alpha-adrenergic vascular tone. On the other hand, in one year experience with 73 patients with UA, 52 did not experience relief from adequate beta-blockade until nifedipine was added. Within 2 hours, 42 of the 52 became asymptomatic--thus indicating that in UA the need for spasmolytic therapy prevails over the need for beta-blockade. In many cases of UA both drugs may have a place however, their exact relative value remains to be established.